GlaxoSmithKline Receives Positive EMEA Opinion For A Conditional Approval Of Tyverb®

GlaxoSmithKline (GSK) announced that Tyverb® (lapatinib) has received a positive opinion recommending a conditional marketing authorisation from the European Medicines Agency (EMEA). Lapatinib, in combination with capecitabine, is indicated for the treatment of patients with advanced or metastatic breast cancer whose tumours over-express ErbB2 (HER2). [click link for full article]

More: continued here

Filed under: Breast Cancer on December 29th, 2007